Appendix 4E & FY26 Annual Report
Filed with ASX · · 59 pages · English
Summary by 6ix AI
The report highlights a revenue increase from operations, although the company reported a loss before tax due to various non-cash items and ongoing investments. The filing also notes that no dividends were declared during the current or prior financial years, and the financial statements have been audited with an unmodified opinion issued.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
PharmX Technologies Limited on 6ix
Earlier from PharmX Technologies
- Appendix 4G & FY26 Corporate Governance Statement
- Notice of FY26 Results Announcement
- H1 FY26 Investor Presentation
- Half Yearly Reports & Accounts
- H1 FY26 Results Announcement
Later from PharmX Technologies
- Announcement of FY26 Results
- FY26 Results Presentation
- 2026 Annual General Meeting - Key Dates
- Pharmx to present at Coffee Microcaps Sydney Conference
- Notification of cessation of securities - PHX
Follow PharmX Technologies into a list and get an email when it puts out news.
Follow PharmX Technologies